Accedi

Bibliografie tematiche / Peritoneal dialysis / Articoli di riviste

Articoli di riviste sul tema "Peritoneal dialysis"

Segui questo link per vedere altri tipi di pubblicazioni sul tema: Peritoneal dialysis.

Autore: Grafiati

Pubblicato: 4 giugno 2021

Ultima modifica: 23 agosto 2023

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Vedi i top-50 articoli di riviste per l'attività di ricerca sul tema "Peritoneal dialysis".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Vedi gli articoli di riviste di molte aree scientifiche e compila una bibliografia corretta.

1

Nakamoto, Hidetomo, Hiroe Imai, Yuji Ishida, Yasuhiro Yamanouchi, Tsutomu Inoue, Hirokazu Okada e Hiromichi Suzuki. "New Animal Models for Encapsulating Peritoneal Sclerosis—Role of Acidic Solution". Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 21, n. 3_suppl (dicembre 2001): 349–53. http://dx.doi.org/10.1177/089686080102103s64.

Testo completo

Abstract (sommario):

Objective Encapsulating peritoneal sclerosis (EPS), in which all or part of the intestine is enveloped in a fibrous ball resembling a cocoon, is a serious complication of peritoneal dialysis (PD). The aim of the present study was to investigate whether pH-neutral or acidic dialysis solutions induce peritoneal fibrosis. Design We divided 18 male Wistar–Kyoto (WKY) rats into three groups and dialyzed them with various solutions as follows: group I, 10 mL acidic dialysis solution (pH 3.8, containing 1.35% glucose), n = 6; group II, 10 mL pH 5.0 dialysis solution, n = 6; and group III, 10 mL neutral dialysis solution (pH 7.0), n = 6. Peritoneal catheters were inserted, and dialysis solution was injected every day for 40 days. At the end of the experiment, a peritoneal equilibration test (PET) was performed. Expression of mRNA of aquaporins 1 and 4 (AQP-1 and AQP-4) in the peritoneum were studied by semiquantitative reverse-transcriptase polymerase chain reaction (RT-PCR). Results In rats treated with pH 3.8 dialysis solution, necropsy findings revealed features identical to those of EPS. The typical appearance was of granulation tissue or fibrotic tissue (or both) covering multiple surfaces. Multiple adhesions were present. In microscopic examinations, peritoneal fibrosis and loss of mesothelium were found. In rats treated with pH 7.0 dialysis solution, no signs of EPS were seen. In rats treated with pH 5.0 dialysis solution, milder changes (subserosal thickening and partial adhesion of the peritonea) were observed. The mRNA of AQP-1 and AQP-4 were expressed in the peritonea of the rats. The expression of the AQPs was significantly suppressed in rats treated with pH 3.8 dialysis solution. Conclusions In rats, long-term intraperitoneal injection of acidic dialysis solution produced features typical of EPS in humans. Newly developed neutral dialysis solutions protected the against the development of EPS during peritoneal dialysis in rats.

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Andreoli, Maria Claudia Cruz, e Claudia Totoli. "Peritoneal Dialysis". Revista da Associação Médica Brasileira 66, suppl 1 (2020): s37—s44. http://dx.doi.org/10.1590/1806-9282.66.s1.37.

Testo completo

Abstract (sommario):

SUMMARY Peritoneal dialysis (PD) is a renal replacement therapy based on infusing a sterile solution into the peritoneal cavity through a catheter and provides for the removal of solutes and water using the peritoneal membrane as the exchange surface. This solution, which is in close contact with the capillaries in the peritoneum, allows diffusion solute transport and osmotic ultrafiltration water loss since it is hyperosmolar to plasma due to the addition of osmotic agents (most commonly glucose). Infusion and drainage of the solution into the peritoneal cavity can be performed in two ways: manually (continuous ambulatory PD), in which the patient usually goes through four solution changes throughout the day, or machine-assisted PD (automated PD), in which dialysis is performed with the aid of a cycling machine that allows changes to be made overnight while the patient is sleeping. Prescription and follow-up of PD involve characterizing the type of peritoneal transport and assessing the offered dialysis dose (solute clearance) as well as diagnosing and treating possible method-related complications (infectious and non-infectious).

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Lu, Jingyuan, Danye Shi, Xinhui Zhao, Minhui Xi, Hualin Qi e Qiang He. "Crocin ameliorates peritoneal fibrosis in rat induced by peritoneal dialysis via Wnt5a/β-Catenin pathway". Quality Assurance and Safety of Crops & Foods 14, n. 4 (1 settembre 2022): 36–44. http://dx.doi.org/10.15586/qas.v14i4.1151.

Testo completo

Abstract (sommario):

Peritoneal dialysis is used in the treatment of patients with kidney diseases. Long-term peritoneal dialysis could result in peritoneal fibrosis and recurrent peritonitis, thus leading to failure of ultrafiltration. Crocin is a bioactive carotenoid and isolated from stigma of Crocus sativus, and ameliorates pulmonary and myocardial fibrosis. The role of crocin in peritoneal fibrosis was assessed. Firstly, rats model with peritoneal dialysis was treated with 4.25% peritoneal dialysate. Results showed that injection with peritoneal dialysate induced obvious hyperplasia and increased thickness in peritoneum structure. Rats with peritoneal dialysis were injected with increasing concentrations of crocin at 10, 20, or 40 mg/kg. Crocin ameliorated the pathological changes in the peritoneum of peritoneal dialysate-induced rats. Secondly, crocin attenuated peritoneal dialysate-induced decrease of E-cadherin, increase of fibronectin, α-smooth muscle actin (α-SMA), and collagen I. Moreover, crocin enhanced ultrafiltration volume and reduced glucose transport in rats model with peritoneal dialysis. Thirdly, crocin also reduced levels of Interleukin (IL)-1β, Tumor Necrosis Factor-α (TNF –α), and IL-6 in peritoneal tissues of rats model with peritoneal dialysis. Lastly, protein expression of Wnt5a and β-Catenin in rats model with peritoneal dialysis were also downregulated by crocin. In conclusion, crocin exerted anti-inflammatory and anti-fibrotic effects on rats model with peritoneal dialysis through inactivation of Wnt5a/β-Catenin pathway.

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Sulowicz, Wladyslaw, Tadeusz Cichocki e Zygmunt Hanicki. "Changes in Activity of Selected Lysosomal Enzymes in Peritoneal Macrophages of Renal Failure Patients on Peritoneal Dialysis". Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 9, n. 4 (ottobre 1989): 313–17. http://dx.doi.org/10.1177/089686088900900417.

Testo completo

Abstract (sommario):

Activity of acid phosphatase (AP), beta-glucuronidase (GR), N-acetyl-beta-D-glucosaminidase (GZ), and peroxidase (P) was assessed using a semiquantitative cytochemical method in peritoneal macro phages of 30 patients with end-stage renal failure treated by intermittent peritoneal dialysis and of 30 control patients with normal renal function. The dialysed patients showed a significantly higher activity of GR and P at the beginning of the treatment as compared with the respective activities observed in the control group and a further significant rise of these activities after 4 months of dialysis. Activity of AP at the beginning of the treatment was insignificantly lower than in the control group and the difference became significant at the end of the investigated period. There was no significant difference between the dialysed patients and the control group in the activity of GZ assessed at the beginning of the dialytic treatment and after 4 months of dialysis. A significant decrease in that activity was, however, observed in the course of dialysis.

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Wieczorowska-Tobis, K., K. Korybalska, A. Polubinska, M. Radkowski, A. Breborowicz e D. G. Oreopoulos. "In Vivo Model to Study the Biocompatibility of Peritoneal Dialysis Solutions". International Journal of Artificial Organs 20, n. 12 (dicembre 1997): 673–77. http://dx.doi.org/10.1177/039139889702001203.

Testo completo

Abstract (sommario):

This study was designed to analyze the complex morphologic and functional effects of dialysis solutions on peritoneum in a rat model on chronic peritoneal dialysis. Peritoneal catheters were inserted into 10 male, Wistar rats and the animals were dialyzed twice daily for 4 weeks with 4.25% Dianeal. During the study we observed two opposite effects: healing of the peritoneum after catheter implantation - decreased cell count in dialysate, decreased permeability of the peritoneum to glucose and total protein, increased volume of drained dialysate; and damage to the membrane due to its exposure to peritoneal dialysis solution - increased hyaluronic acid levels in dialysate, a tendency of the peritoneum to thicken when compared to non-dialyzed animals. Our rat model of CAPD may be used for quantitative and qualitative assessment of the effects of peritoneal dialysis solution on the peritoneum during chronic dialysis

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Wu, George, Katarzyna Wieczorowska Tobis, Alicja Polubinska, Katarzyna Korybalska, Violetta Filas, Paul Tam, Ian French e Andrzej Breborowicz. "N-Acetylglucosamine Changes Permeability of Peritoneum during Chronic Peritoneal Dialysis in Rats". Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 18, n. 2 (marzo 1998): 217–24. http://dx.doi.org/10.1177/089686089801800212.

Testo completo

Abstract (sommario):

Objective To evaluate the effect of supplementation of dialysis fluid with N-acetylglucosamine (NAG) on the permeability of peritoneum during chronic peritoneal dialysis in rats. Design Experiments were performed on rats with surgically implanted peritoneal catheters. Dialysis solution [DianeaI1.5% (Baxter, Deerfield, IL, U.S.A.) supplemented with either NAG 50 mmol/L or glucose 50 mmol/L (control)] was infused intraperitoneally twice, every day, for 8 weeks. Peritoneal equilibration tests (PET) were performed in all animals at the beginning of the study and after 8 weeks of dialysis. Additionally, at the end of each week, dialysis solution infused in the morning was drained after 4 hours of intraperitoneal dwell. White blood cell count, creatinine, and total protein concentrations were measured in the effluent dialysate. After 8 weeks of dialysis, the morphology of the peritoneum was studied. Results In rats exposed to dialysis fluid supplemented with NAG, peritoneal permeability to creatinine and proteins was reduced when compared to animals dialyzed with glucose solution. In NAG treated animals, staining with alcian blue for polyanions in the peritoneal interstitium was significantly stronger than in rats dialyzed with glucose solution. Conclusions Chronic peritoneal dialysis with dialysis solution supplemented with N-acetylglucosamine causes accumulation of glycosaminoglycans in the peritoneal interstitium, which results in a change of peritoneal permeability.

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Kostović, Milica, Milica Cvetkovic e Dejan Petrovic. "Gastrointestinal Non-Infectious Complications in Patients on Peritoneal Dialysis". Serbian Journal of Experimental and Clinical Research 17, n. 2 (1 giugno 2016): 153–60. http://dx.doi.org/10.1515/sjecr-2015-0039.

Testo completo

Abstract (sommario):

Abstract Gastrointestinal complications are common among patients on peritoneal dialysis. Risk factors for the development of gastrointestinal complications in this patient population include: toxic effects of uremic toxins, frequent use of nonsteroidal anti-inflammatory drugs, Helicobacter pylori infection, angiodysplasia, increased intra-abdominal pressure, use of bioincompatible solution for peritoneal dialysis, increased glucose in solutions for peritoneal dialysis, secondary hyperparathyroidism (hypercalcemia), a disorder of lipid metabolism (hypertriglyceridemia), and the duration of peritoneal dialysis treatment. The most important non-infectious gastrointestinal complications in patients on peritoneal dialysis are: gastrointestinal bleeding, herniation and leaking of the dialysate from the abdomen (increased intra-abdominal pressure), impaired lung function (intra-abdominal hypertension), acute pancreatitis, and encapsulating sclerosis of the peritoneum. Intra-abdominal hypertension is defined as IAP ≥ 12 mmHg. Pouring the peritoneal dialysis solution leads to increased intra-abdominal pressure, which results in the development of hernias, pleuro-peritoneal dialysate leakage (hydrothorax), and restrictive pulmonary dysfunction. Risk factors for the development of acute pancreatitis in this patient population include: uraemia, secondary hyperparathyroidism with hypercalcemia, hypertriglyceridemia, features of the peritoneal dialysis solution (osmolarity, acidity, glucose, chemical irritation, and calcium in the solution for peritoneal dialysis lead to “local hypercalcemia”), toxic substances from the dialysate, the bags and tubing, and peritonitis and treatment of peritonitis with antibiotics and anticoagulants. Encapsulating sclerosis of the peritoneum is rare and is the most serious complication of long-term peritoneal dialysis. It is characterized by thickening of the peritoneum, including cancer, and signs and symptoms of obstructive ileus. Diagnosis is based on clinical, laboratory and radiological parameters. Encapsulating sclerosis of the peritoneum can be indicated by an AR-CA-125 concentration of less than 33 U/min and a concentration of AR-IL-6 greater than 350 pg/min in the effluent of patients with ultrafiltration weakness. Treatment consists of stopping peritoneal dialysis, using anti-inflammatory (corticosteroids) and anticicatricial drugs (tamoxifen), while surgical treatment includes enterolysis and adhesiolysis.

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Djurdjevic-Mirkovic, Tatjana. "Peritoneal dialysis - experiences". Medical review 63, n. 11-12 (2010): 753–57. http://dx.doi.org/10.2298/mpns1012753d.

Testo completo

Abstract (sommario):

Peritoneal dialysis is the method of treatment of terminal-stage chronic kidney failure. Nowadays, this method is complementary to haemodialysis. It is based on the principles of the diffusion of solutes and ultrafiltration of fluids across the peritoneal membrane, which acts as a filter. The dialysate is introduced into the peritoneum via the previously positioned peritoneal catheter. The peritoneal dialysis is carried out on daily basis, at home by the patient, and the ?exchange? is repeated 4-5 times during the 24 hours. The first steps in peritoneal dialysis at the Department for Haemodialysis of the Clinical Centre of Vojvodina date back to 1973. Until 1992, the patients were subjected to this program only sporadically. Since 1998 the peritoneal dialysis method has been performed at the Clinic for Nephrology and Clinical Immunology. In the period 1998-2008 ninety nine peritoneal catheters were placed. Chronic glomerulonephritis, nephroangiosclerosis and diabetes were identified as the most common causes of chronic renal failure. Two methods of catheter placement were applied: the standard open surgery method (majority of patients) and laparoscopy. Most of the patients were subjected to continuous ambulatory peritoneal dialysis, whereas four patients received automatic dialysis. Transplantation was performed in 10 patients, i.e. cadaveric transplantation and living-related donor transplantation, each in 5 patients. Peritoneal dialysis was available as a service outside our institution as well. A ten-year experience in peritoneal dialysis gained at our Centre has proved the advantages and qualities of this method, strongly supporting its wider application in the treatment of terminal-stage chronic kidney failure.

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Hirahara, Ichiro, Eiji Kusano, Satoru Yanagiba, Yukio Miyata, Yasuhiro Ando, Shigeaki Muto e Yasushi Asano. "Peritoneal Injury by Methylglyoxal in Peritoneal Dialysis". Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 26, n. 3 (maggio 2006): 380–92. http://dx.doi.org/10.1177/089686080602600317.

Testo completo

Abstract (sommario):

Background Peritoneal dialysis (PD) is a common treatment for patients with reduced or absent renal function. Long-term PD leads to peritoneal injury with structural changes and functional decline, such as ultrafiltration loss. At worst, peritoneal injury leads to encapsulating peritoneal sclerosis, a serious complication of PD. Glucose degradation products contained in PD fluids contribute to the bioincompatibility of conventional PD fluids. Methylglyoxal (MGO) is an extremely toxic glucose degradation product. The present study examined the injurious effect of MGO on peritoneum in vivo. Methods Male Sprague–Dawley rats ( n = 6) were administered PD fluids (pH 5.0) containing 0, 0.66, 2, 6.6, or 20 mmol/L MGO every day for 21 days. On day 22, peritoneal function was estimated by the peritoneal equilibration test. Drained dialysate was analyzed for type IV collagen-7S, matrix metalloproteinase (MMP), and vascular endothelial growth factor (VEGF). Histological analysis was also performed. Results In rats receiving PD fluids containing more than 0.66 mmol/L MGO, peritoneal function decreased significantly and levels of type IV collagen-7S and MMP-2 in drained dialysate increased significantly. In the 20-mmol/L MGO-treated rats, loss of body weight, expression of VEGF, thickening of the peritoneum, and formation of abdominal cocoon were induced. MMP-2 and VEGF were produced by infiltrating cells in the peritoneum. Type IV collagen was detected in basement membrane of microvessels. Conclusion MGO induced not only peritoneal injury but also abdominal cocoon formation in vivo. The decline of peritoneal function may result from reconstitution of microvessel basement membrane or neovascularization.

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Kowalewska, Paulina M., Peter J. Margetts e Alison E. Fox-Robichaud. "Peritoneal Dialysis Catheter Increases Leukocyte Recruitment in the Mouse Parietal Peritoneum Microcirculation and Causes Fibrosis". Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 36, n. 1 (gennaio 2016): 7–15. http://dx.doi.org/10.3747/pdi.2014.00211.

Testo completo

Abstract (sommario):

♦BackgroundThe objective of this study was to examine the effects of a conventional dialysis solution and peritoneal catheter on leukocyte- endothelial cell interactions in the microcirculation of the parietal peritoneum in a subacute peritoneal dialysis (PD) mouse model.♦MethodsAn intraperitoneal (IP) catheter with a subcutaneous injection port was implanted into mice and, after a 2-week healing period, the animals were injected daily for 6 weeks with a 2.5% dextrose solution. Intravital microscopy (IVM) of the parietal peritoneum microcirculation was performed 4 hours after the last injection of the dialysis solution. Leukocyte-endothelial cell interactions were quantified and compared with catheterized controls without dialysis treatment and naïve mice.♦ ResultsThe number of rolling and extravascular leukocytes along with peritoneal fibrosis and neovascularization were significantly increased in the catheterized animals compared with naïve mice but did not significantly differ between the 2 groups of catheterized animals with sham injections or dialysis solution treatment.♦ConclusionThe peritoneal catheter implant increased leukocyte rolling and extravasation, peritoneal fibrosis and vascularization in the parietal peritoneum independently from the dialysis solution treatment.

Gli stili APA, Harvard, Vancouver, ISO e altri

11

Mushahid, Ali, Farooq Aadil, Ghosh Soumyodhriti, Nagpure Amit, Sharma Deendayal, Mujalde Vikram Singh, Gupta Shilpi e Mathur Praveen. "Peritoneal Dialysis Cannulations-Our Experience". Scholars Journal of Applied Medical Sciences 4, n. 6 (giugno 2016): 1878–80. http://dx.doi.org/10.21276/sjams.2016.4.6.2.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

12

RADULESCU, Daniela, Dragos Adrian GEORGESCU, Andrei ANGELESCU e Bogdan Florin GEAVLETE. "Abdominal Pseudocyst in the Vicinity of Calcified Renal Allograft in a Patient with Peritoneal Dialysis - Case Report". Medicina Moderna - Modern Medicine 27, n. 3 (26 settembre 2020): 237–40. http://dx.doi.org/10.31689/rmm.2020.27.3.237.

Testo completo

Abstract (sommario):

Abdominal pseudocysts are rarely reported in peritoneal dialysis and usually arise secondary to repeated dialysisrelated peritonitis. We present the case of a patient with end-stage renal disease treated for 9 years by continuous ambulatory peritoneal dialysis that developed an abdominal pseudocyst in the vicinity of the non-functional and calcifi ed renal graft. Because the adequacy of peritoneal dialysis was optimal, surgical removal of the invaginated peritoneum and closure of the breach allowed the patient to continue peritoneal dialysis treatment.

Gli stili APA, Harvard, Vancouver, ISO e altri

13

Catalan, Marina Penélope, Jaime Esteban, Dolores Subirá, Jesús Egido e Alberto Ortiz. "Inhibition of Caspases Improves Bacterial Clearance in Experimental Peritonitis". Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 23, n. 2 (marzo 2003): 123–26. http://dx.doi.org/10.1177/089686080302300205.

Testo completo

Abstract (sommario):

Background Inhibition of caspases improves the antibacterial capacity of leukocytes cultured with peritoneal dialysis solutions, and improves the prognosis of septic, polymicrobial experimental peritonitis. Objective To test whether inhibition of caspases alters the evolution of peritonitis in the presence of peritoneal dialysis solution. Design 32 mice were assigned to therapy with either the pan-caspase inhibitor zVAD or vehicle for 48 hours following infection with Staphylococcus aureus, in the presence of lactate-buffered, 4.25% glucose peritoneal dialysis solution. 16 mice received vehicle in phosphate-buffered saline. Main Outcome Measure Number of bacteria recovered from the peritoneum at 48 hours. Results Peritoneal dialysis solution accelerated leukocyte apoptosis. zVAD decreased the number of apoptotic peritoneal leukocytes and the number of bacteria recovered from the peritoneum at 48 hours (zVAD 2.8 ± 0.3 vs vehicle 3.9 ± 0.2 log colony forming units of S. aureus, p = 0.007). Conclusions Inhibition of caspases accelerates peritoneal bacterial clearance in the presence of peritoneal dialysis solutions in vivo in the experimental setting. Inhibition of caspases should be explored as a mean to accelerate recovery following peritonitis in the clinical setting.

Gli stili APA, Harvard, Vancouver, ISO e altri

14

Akimoto, Tetsu, Tomoyuki Yamazaki, Marina Kohara, Saki Nakagawa, Yoshihiko Kanai, Sayoko Izawa, Hisashi Yamamoto et al. "Pleuroperitoneal Communication and Ovarian Cancer Complicating Peritoneal Dialysis: A Case Report of a Patient with End-Stage Kidney Disease". Clinical Medicine Insights: Case Reports 10 (1 gennaio 2017): 117954761773581. http://dx.doi.org/10.1177/1179547617735818.

Testo completo

Abstract (sommario):

Peritoneal dialysis has been a widely accepted modality for treating end-stage kidney disease, but a regular dialysis schedule can be seriously disrupted by various comorbid conditions requiring surgical intervention. A 40-year-old woman who had been receiving peritoneal dialysis was sequentially but separately complicated by pleuroperitoneal communication and ovarian cancer. Despite the need for temporary interruption of her peritoneal dialysis schedule, it was successfully resumed after the relevant surgeries for each disease. Several concerns regarding overall postoperative dialytic management strategies, including how to deal with the peritoneal dialysis catheter during the postoperative period as well as how long peritoneal dialysis should be interrupted, which remain an unresolved issue in the field of nephrology, are also discussed.

Gli stili APA, Harvard, Vancouver, ISO e altri

15

Santoboni, Alberto. "Peritoneal dialysis: Marginal dialysis?" Giornale di Tecniche Nefrologiche e Dialitiche 26, n. 5_suppl (gennaio 2014): 46–47. http://dx.doi.org/10.5301/gtnd.2014.11915.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

16

Gabella, Paolo, Francesca Bermond, Cristiana Bagnis e Martino Marangella. "Peritoneal dialysis: Marginal dialysis". Giornale di Tecniche Nefrologiche e Dialitiche 26, n. 5_suppl (gennaio 2014): 44–45. http://dx.doi.org/10.5301/gtnd.2014.11966.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

17

Dinarvand, Peyman, Seyed Mahdi Hassanian Mehr e Alireza R. Rezaie. "Activated Protein C Prevents Peritoneal Fibrosis". Blood 124, n. 21 (6 dicembre 2014): 4229. http://dx.doi.org/10.1182/blood.v124.21.4229.4229.

Testo completo

Abstract (sommario):

Abstract Patients with chronic kidney disease require dialysis (hemodialysis or peritoneal dialysis) for treatment. Peritoneal dialysis is an alternative to hemodialysis for the treatment of end-stage renal disease and is based on the use of the peritoneum as a permeable membrane where ultrafiltration and diffusion between dialysate and blood can take place across the peritoneum. Peritoneal fibrosis is one of the main complications of peritoneal dialysis and affects up to 20% of patients undergoing continuous ambulatory peritoneal fibrosis. The exact mechanism of this process has yet to be elucidated and no effective therapy for the problem has been established. APC is a natural vitamin-K dependent anticoagulant protease, which also has potent antiinflammatory activity. We hypothesized that the antiinflammatory function of APC may inhibit dialysis-mediated peritoneal fibrosis. To test this hypothesis, we generated a chlorhexidine gluconate (CG)-induced peritoneal fibrosis model by injecting CG to male C57BL/6 mice for 21 days with or without intraperitoneal administration of a low dose of recombinant APC (50 µg/kg/day bodyweight) one hour before injecting CG. At 10 and 21 days after injection, the mice were sacrificed and the parietal peritoneum and omentom were dissected for histological evaluation and for analysis of expression of inflammatory molecules. Strikingly, we discovered that APC inhibits the thickness of peritoneal fibrosis and potently inhibits the mRNA expression of TGF-b1, cytokeratins, a2-integrin, MMP-2 and 9 and also significantly increases the mRNA expression of TIMP-2 in peritoneal tissues of the experimental animals. We also discovered that APC significantly decreases the concentration of TGF-b1 and dramatically increases the concentration of tPA in peritoneal fluids. Taken together, our findings suggest that APC may have therapeutic potential in ameliorating dialysis-mediated peritoneal fibrosis. Disclosures No relevant conflicts of interest to declare.

Gli stili APA, Harvard, Vancouver, ISO e altri

18

Krishnan, Rajesh G., Milos V. Ognjanovic, Jean Crosier e Malcolm G. Coulthard. "Acute Hydrothorax Complicating Peritoneal Dialysis". Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 27, n. 3 (maggio 2007): 296–99. http://dx.doi.org/10.1177/089686080702700315.

Testo completo

Abstract (sommario):

Aim To determine whether gradually increasing the peritoneal dialysate fill volume from 10 to 40 mL/kg over 6 days, rather than commencing at 40 mL/kg, prevents hydrothorax in children and reverses it if present. Methods A review of children peritoneally dialyzed in a single center. Results During the 20 years beginning June 1985, 416 children were peritoneally dialyzed, of which 327 (79%) had acute and 89 had end-stage renal failure. Among 253 children who had gradually increasing fill volumes, none developed acute hydrothoraces, but 13/163 (8%) who began with 40 mL/kg cycles did ( p < 0.000, Fisher's exact test). These were diagnosed after a median (range) of 48 (6 – 72) hours and were predominantly right sided. Initially, we readily abandoned peritoneal dialysis; 2 were changed to hemodialysis. Subsequently, we found that peritoneal dialysis could be continued by using small volumes with the patients sitting up; cycle volumes were then gradually increased again. One pre-term baby died soon after developing an acute hydrothorax. One patient on chronic peritoneal dialysis developed an acute hydrothorax after forceful vomiting, but recovered after being dialyzed sitting up with low fills. Conclusion Acute hydrothorax can be prevented and treated using graduated cycle volumes, and is not a contraindication for peritoneal dialysis.

Gli stili APA, Harvard, Vancouver, ISO e altri

19

Redmond, Avril, e Elizabeth Doherty. "Peritoneal dialysis". Nursing Standard 19, n. 40 (15 giugno 2005): 55–66. http://dx.doi.org/10.7748/ns.19.40.55.s55.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

20

Redmond, Avril, e Elizabeth Doherty. "Peritoneal dialysis". Nursing Standard 19, n. 40 (15 giugno 2005): 55–65. http://dx.doi.org/10.7748/ns2005.06.19.40.55.c3893.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

21

Gould, Caroline. "Peritoneal dialysis". Nursing Standard 20, n. 3 (28 settembre 2005): 67–68. http://dx.doi.org/10.7748/ns.20.3.67.s73.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

22

Gokal, Ram. "Peritoneal Dialysis". Drugs & Aging 17, n. 4 (ottobre 2000): 269–82. http://dx.doi.org/10.2165/00002512-200017040-00003.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

23

Teitelbaum, Isaac. "Peritoneal Dialysis". New England Journal of Medicine 385, n. 19 (4 novembre 2021): 1786–95. http://dx.doi.org/10.1056/nejmra2100152.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

24

Fung, Winston Wing-Shing, Jack Kit-Chung Ng e Philip Kam-Tao Li. "Peritoneal Dialysis". Nephrology Self-Assessment Program 20, n. 1 (agosto 2021): 19–34. http://dx.doi.org/10.1681/nsap.2021.20.1.2.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

25

Taskapan, Hulya, Olof Heimburger, Cengiz Utas e Paul Tam. "Peritoneal Dialysis". International Journal of Nephrology 2011 (2011): 1. http://dx.doi.org/10.4061/2011/218974.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

26

Twardowski, Zbylut J. "Peritoneal dialysis". Postgraduate Medicine 85, n. 5 (aprile 1989): 161–82. http://dx.doi.org/10.1080/00325481.1989.11700663.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

27

Lum, Gary M. "Peritoneal dialysis". Critical Care Medicine 27, n. 11 (novembre 1999): 2595–96. http://dx.doi.org/10.1097/00003246-199911000-00058.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

28

Kratochwill, K., M. Boehm, R. Herzog, L. Kuster, A. Gleiss, C. Aufricht, A. Vychytil et al. "PERITONEAL DIALYSIS". Nephrology Dialysis Transplantation 29, suppl 3 (1 maggio 2014): iii16—iii18. http://dx.doi.org/10.1093/ndt/gfu114.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

29

HATHAWAY, LISA. "Peritoneal dialysis". Nursing Made Incredibly Easy! 2, n. 5 (settembre 2004): 55–58. http://dx.doi.org/10.1097/00152258-200409000-00011.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

30

Chaimovitz, Cidio. "Peritoneal dialysis". Kidney International 45, n. 4 (aprile 1994): 1226–40. http://dx.doi.org/10.1038/ki.1994.163.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

31

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 42, n. 2 (aprile 1996): 102–4. http://dx.doi.org/10.1097/00002480-199642020-00022.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

32

Choi, Peter, e Edwina A. Brown. "Peritoneal Dialysis". Medicine 31, n. 6 (giugno 2003): 70–73. http://dx.doi.org/10.1383/medc.31.6.70.28314.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

33

Burkart, John M. "Peritoneal Dialysis". Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 17, n. 3_suppl (giugno 1997): 5–7. http://dx.doi.org/10.1177/089686089701703s01.

Testo completo

Abstract (sommario):

These presentations highlighted some of the current research needs in peritoneal dialysis. They are not meant to eclipse other important issues, such as adequacy and nutrition. These needs have become apparent as the therapy has evolved and progressed. They in fact are a testament to the increasing acceptance, use, and development of the therapy and suggest that there is potential for even further advancement for the therapy of peritoneal dialysis in the future.

Gli stili APA, Harvard, Vancouver, ISO e altri

34

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 43, n. 2 (marzo 1997): 79–81. http://dx.doi.org/10.1097/00002480-199743020-00014.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

35

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 44, n. 2 (marzo 1998): 78A. http://dx.doi.org/10.1097/00002480-199803000-00291.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

36

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 44, n. 2 (marzo 1998): 78A. http://dx.doi.org/10.1097/00002480-199803000-00292.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

37

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 44, n. 2 (marzo 1998): 78A. http://dx.doi.org/10.1097/00002480-199803000-00293.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

38

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 44, n. 2 (marzo 1998): 79A. http://dx.doi.org/10.1097/00002480-199803000-00294.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

39

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 44, n. 2 (marzo 1998): 79A. http://dx.doi.org/10.1097/00002480-199803000-00295.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

40

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 44, n. 2 (marzo 1998): 79A. http://dx.doi.org/10.1097/00002480-199803000-00296.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

41

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 44, n. 2 (marzo 1998): 79A. http://dx.doi.org/10.1097/00002480-199803000-00297.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

42

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 44, n. 2 (marzo 1998): 80A. http://dx.doi.org/10.1097/00002480-199803000-00298.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

43

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 44, n. 2 (marzo 1998): 80A. http://dx.doi.org/10.1097/00002480-199803000-00299.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

44

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 44, n. 2 (marzo 1998): 81A. http://dx.doi.org/10.1097/00002480-199803000-00300.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

45

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 44, n. 2 (marzo 1998): 81A. http://dx.doi.org/10.1097/00002480-199803000-00302.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

46

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 44, n. 2 (marzo 1998): 81A. http://dx.doi.org/10.1097/00002480-199803000-00303.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

47

&NA;. "PERITONEAL DIALYSIS". ASAIO Journal 44, n. 2 (marzo 1998): 82A. http://dx.doi.org/10.1097/00002480-199803000-00304.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

48

Kunze, R., S. Witt, J. Vienken, K. Rie, N. Masayoshi, K. Aritoshi, O. Yoshinaga et al. "Peritoneal dialysis". Clinical Kidney Journal 4, suppl 2 (1 giugno 2011): 4.s2.25. http://dx.doi.org/10.1093/ndtplus/4.s2.25.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

49

Kang, Y. S., J. J. Cha, Y. Y. Hyun, M. H. Lee, H. K. Song, D. R. Cha, K. Bang et al. "Peritoneal dialysis". Clinical Kidney Journal 4, suppl 2 (1 giugno 2011): 4.s2.54. http://dx.doi.org/10.1093/ndtplus/4.s2.54.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

50

Ellam, Tim, e Martin Wilkie. "Peritoneal dialysis". Medicine 35, n. 8 (agosto 2007): 466–69. http://dx.doi.org/10.1016/j.mpmed.2007.05.011.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!